Yahoo Poland Wyszukiwanie w Internecie

Search results

1. edrn.nci.nih.gov › data-and-resources › biomarkersOVA1 — Early Detection Research Network

   edrn.nci.nih.gov › data-and-resources › biomarkers

   • Zapisane w pamięci cache

   OVA1 is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) of Proteomic Biomarkers test that analyzes the serum levels of these five proteomic biomarkers. OVA1 is the first FDA approved test for assessing ovarian cancer risk in women previously diagnosed with an ovarian mass, and already scheduled for surgery.

   • Associate Membership Program

     The Associate Membership is designed for investigators who...

   • Memoranda of Understanding

     Two documents describing an understanding between EDRN and...

   • Log In

     The EDRN Cancer Biomarker Data Commons has both public and...

   • Standard Operating Procedures

     Ovarian Blood SOP; Ovarian Uterine Lavage SOP; Pancreas...

   • FDA-Approved Tests

     OVA1™ (5 analytes: CA 125, prealbumin, apolipoprotein A-1,...

   • Data

     A data sharing resource, Laboratory Archive and Catalog...

   • CLIA-Approved Markers

     Blood test validated to detect lung cancer from...

   • Statistical Resources

     Resources for the two statistical groups, Zheng and Huang

2. www.ncbi.nlm.nih.gov › pmc › articlesMolecular Biomarkers for the Early Detection of Ovarian Cancer

   www.ncbi.nlm.nih.gov › pmc › articles

   10 paź 2022 · Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and often occurs due to a lack of specific symptoms and effective biomarkers for an early detection.

3. www.ncbi.nlm.nih.gov › pmc › articlesCA125 and Ovarian Cancer: A Comprehensive Review - PMC

   www.ncbi.nlm.nih.gov › pmc › articles

   11 gru 2020 · OVA1 is another panel of 5 biomarkers, including CA125, Transthyretin, Apolipoprotein A1, Transferrin, and B2-microglobulin, used to distinguish between the high and low risk of ovarian cancer for patients with pelvic masses.

4. pubmed.ncbi.nlm.nih.gov › 34441373Salvaging Detection of Early-Stage Ovarian Malignancies When ......

   pubmed.ncbi.nlm.nih.gov › 34441373

   10 sie 2021 · OVA1 detected over 50% of ovarian malignancies in premenopausal women despite a low-risk serum CA125. OVA1 also correctly identified 63% of early-stage cancers missed by CA125. The most common epithelial ovarian cancer subtypes in the study population were mucinous (25%) and serous (23%) carcinomas.

5. www.ncbi.nlm.nih.gov › pmc › articlesBiomarkers in Ovarian Pathology: From Screening to Diagnosis....

   www.ncbi.nlm.nih.gov › pmc › articles

   29 paź 2021 · This article provides an overview of the current state of ovarian cancer biomarker research, highlighting the main gaps in this knowledge and providing recommendations that could help reduce OC morbidity and mortality by focusing on promising research topics and technologies that could promote early detection.

6. www.thelancet.com › journals › ebiomMulti-omics approaches for biomarker discovery in early ovarian...

   www.thelancet.com › journals › ebiom

   17 lis 2021 · Ovarian cancer (OC) is the eighth most common cause of cancer mortality in women worldwide, accounting for over 310,000 new cases and around 200,000 deaths in 2020. 1 Epithelial ovarian cancer (EOC), a heterogeneous disease characterized by great molecular and histological diversity, represents approximately 90% of OC, with high-grade serous ...

7. pubmed.ncbi.nlm.nih.gov › 22582125An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for...

   pubmed.ncbi.nlm.nih.gov › 22582125

   In this review, OVA1® (Vermillion, Inc., Austin, TX), the first in vitro diagnostic multivariate index assay (IVDMIA) of protein biomarkers cleared by the US Food and Drug Administration (FDA), is used to explain the concept behind IVDMIA, the use of multiple markers to improve clinical performance ….